Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qufeng Zhitong capsule plus methotrexate for rheumatoid arthritis
ChiCTR2200060763Phase 4Not yet recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of qufeng zhitong jiaonang and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Guang'anmen Hospital. Primary endpoints: Proportion of subjects achieving ACR20 and Safety indicators. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
qufeng zhitong jiaonangmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2200060763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060763.